A randomized, controlled study of peginterferon lambda-1a/ribavirin +/- daclatasvir for hepatitis C virus genotype 2 or 3 by Foster, Graham R. et al.
Foster et al. SpringerPlus  (2016) 5:1365 
DOI 10.1186/s40064-016-2920-z
RESEARCH
A randomized, controlled 
study of peginterferon lambda-1a/
ribavirin ± daclatasvir for hepatitis C virus 
genotype 2 or 3
Graham R. Foster1, Kazuaki Chayama2, Wan‑Long Chuang3, Hugo Fainboim4, Martti Farkkila5, Adrian Gadano6, 
Giovanni B. Gaeta7, Christophe Hézode8, Yukiko Inada9, Jeong Heo10, Hiromitsu Kumada11, Sheng‑Nan Lu12, 
Patrick Marcellin13, Christophe Moreno14, Stuart K. Roberts15,16, Simone I. Strasser17, Alexander J. Thompson18, 
Joji Toyota19, Seung Woon Paik20, John M. Vierling21, Anna L. Zignego22, David Cohen23, 
Fiona McPhee24, Megan Wind‑Rotolo25, Subasree Srinivasan26*, Matthew Hruska27, Heather Myler28 
and Simon D. Portsmouth26,29
Abstract 
Background and purpose: Peginterferon Lambda was being developed as an alternative to alfa interferon for the 
treatment of chronic hepatitis C virus (HCV) infection. We compared peginterferon Lambda‑1a plus ribavirin (Lambda/
RBV) and Lambda/RBV plus daclatasvir (DCV; pangenotypic NS5A inhibitor) with peginterferon alfa‑2a plus RBV (alfa/
RBV) in treatment‑naive patients with HCV genotype 2 or 3 infection.
Methods: In this multicenter, double‑blind, phase 3 randomized controlled trial, patients were assigned 2:2:1 to 
receive 24 weeks of Lambda/RBV, 12 weeks of Lambda/RBV + DCV, or 24 weeks of alfa/RBV. The primary outcome 
measure was sustained virologic response at post‑treatment Week 12 (SVR12).
Results: Overall, 874 patients were treated: Lambda/RBV, n = 353; Lambda/RBV + DCV, n = 349; alfa/RBV, n = 172. 
Patients were 65 % white and 33 % Asian, 57 % male, with a mean age of 47 years; 52 % were infected with genotype 2  
(6 % cirrhotic) and 48 % with genotype 3 (9 % cirrhotic). In the Lambda/RBV + DCV group, 83 % (95 % confidence 
interval [CI] 78.5, 86.5) achieved SVR12 (90 % genotype 2, 75 % genotype 3) whereas SVR12 was achieved by 68 % 
(95 % CI 63.1, 72.9) with Lambda/RBV (72 % genotype 2, 64 % genotype 3) and 73 % (95 % CI 66.6, 79.9) with peginter‑
feron alfa/RBV (74 % genotype 2, 73 % genotype 3). Lambda/RBV + DCV was associated with lower incidences of 
flu‑like symptoms, hematological abnormalities, and discontinuations due to adverse events compared with alfa/RBV.
Conclusion: The 12‑week regimen of Lambda/RBV + DCV was superior to peginterferon alfa/RBV in the combined 
population of treatment‑naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile 
compared with alfa/RBV.
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Background
Chronic hepatitis C virus (HCV) infection affects up to 
170 million people worldwide based on serologic data 
(Lavanchy 2009), resulting in approximately 500,000 
deaths each year (World Health Organization 2012). 
HCV comprises 7 major genotypes and 67 subtypes; gen-
otypes 1, 2, and 3 are the most widely distributed and the 
most studied therapeutically (Smith et  al. 2014). Geno-
type 2 is prevalent in South America and Asia, whereas 
genotype 3 is common in Europe (European Association 
for the Study of the Liver 2014), the United States, Aus-
tralia, and southern Asia (Ansaldi et al. 2014).
Previously, HCV genotype 2 or 3 infection was treated 
primarily with 24 weeks of peginterferon alfa-2a plus rib-
avirin (alfa/RBV). Alfa/RBV therapy is subject to a num-
ber of limitations; among these are frequent, sometimes 
treatment-limiting adverse events (AEs) including hemo-
lytic anemia and other cytopenias (Sulkowski et al. 2011). 
Genotype 3 infection has been associated with poorer 
outcomes than genotype 2, including a higher inci-
dence of steatosis (Matos et  al. 2006), accelerated fibro-
sis (Bochud et al. 2009; Probst et al. 2011), increased risk 
of hepatocellular cancer, and lower sustained virologic 
response (SVR) rates following treatment with alfa/RBV 
or oral direct-acting antiviral (DAA)-based regimens 
(Zeuzem et al. 2004; Andriulli et al. 2008).
Oral DAA regimens are now replacing interferon-based 
treatment for chronic HCV infection; however, DAA 
options for genotypes 2 and 3 are more restricted than 
those for genotype 1. Currently approved regimens for 
genotype 2-infected patients include sofosbuvir (SOF) plus 
RBV and peginterferon plus RBV in the US and EU, and 
SOF plus velpatasvir (VEL) in the US. Approved regimens 
for genotype 3-infected patients include combinations of 
SOF plus RBV, SOF plus daclatasvir (DCV) with or with-
out RBV, SOF plus peginterferon and RBV, and peginter-
feron plus RBV; in addition, SOF plus VEL was recently 
approved in the US (Bristol Myers Squbb Pharmaceuti-
cals Ltd 2014; Bristol-Myers Squibb 2016). DCV +  SOF 
with or without RBV is a preferred option for treating 
HCV genotype 3-infected patients according to guidelines 
issued by the American Association for the Study of Liver 
Disease and the European Association for the Study of 
the Liver (European Association for the Study of the Liver 
2014; AASLD/IDSA HCV Guidance Panel 2015).
Peginterferon lambda-1a (Lambda) is a pegylated Type III 
interferon with HCV antiviral activity similar to that 
of alfa interferons; however, Lambda utilizes a unique 
receptor with more restricted tissue distribution than 
the alfa receptor (Andersen et  al. 2013). In the phase 2 
EMERGE study, similar SVR rates were achieved with 
Lambda/RBV and alfa/RBV in previously untreated gen-
otype 1–4 infection. However, Lambda/RBV exhibited 
improved tolerability characterized by fewer musculo-
skeletal and influenza-like events (Muir et  al. 2014) and 
a better hematologic profile, including amelioration of 
RBV-associated anemia through compensatory erythro-
poiesis (Everson et al. 2011).
Daclatasvir (DCV) is an NS5A replication complex 
inhibitor DAA with in  vitro activity and clinical data 
against HCV genotypes 1–6 (Hézode et  al. 2016; Wel-
zel et al. 2016; Sulkowski et al. 2014; Gao 2013; Poordad 
et  al. 2016; Nelson et  al. 2015; Wyles et  al. 2015). DCV 
has been approved in the US, Europe, Japan, and multi-
ple countries across the Americas, Middle East, and Asia 
Pacific region. We report the results of a phase 3 study 
of Lambda/RBV, with and without DCV, versus alfa/RBV 
in previously untreated patients with genotype 2 or 3 
infection.
Methods
Study design
This randomized, double-blind, multinational phase 3 
study (ClinicalTrials.gov identifier NCT01616524) 
enrolled treatment-naive patients with genotype 2 or 
3 infection from 124 clinical centers in 18 countries in 
Europe (Belgium, Finland, France, Greece, Italy, Nether-
lands, United Kingdom), Asia (Japan, Korea, Singapore, 
Hong Kong, Taiwan), and South America (Argentina, 
Mexico), plus the USA, Russia, Australia, and New Zea-
land between 20 July 2012 and 15 August 2013. Eligi-
ble patients were randomly assigned 2:2:1 to treatment 
with either (a) 24 weeks of Lambda/RBV (first 12 weeks 
with a DCV placebo); (b) 12 weeks of Lambda/RBV plus 
DCV 60 mg once daily, or (c) 24 weeks of alfa/RBV (first 
12 weeks with a DCV placebo). Patients receiving 24 or 
12 weeks of therapy were followed up for 24 or 48 weeks 
post-treatment, respectively. Both peginterferons were 
self-administered at a dose of 180 μg once weekly by sub-
cutaneous injection. RBV 400 mg was taken orally twice 
daily with food. DCV 60 mg was taken orally once daily, 
with or without food.
Randomization was via an interactive voice response 
system designated by the study sponsor. Randomization 
was stratified by baseline HCV RNA (<800,000 IU/mL or 
≥800,000  IU/mL), cirrhosis status, region (Japan vs the 
rest of the world), and HCV genotype. Study enrolment 
was capped by genotype (neither genotype 2 nor 3 could 
comprise more than 60 % of total enrollment), cirrhosis 
status (no more than 20 % of patients with compensated 
cirrhosis in any treatment arm), and region (Japanese 
patients limited to approximately 70 overall).
Ethics, consent and permissions
This study was conducted in accordance with Good Clin-
ical Practice guidelines and in accordance with the ethical 
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principles originating in the Declaration of Helsinki. All 
patients provided written informed consent. The study 
protocol and all relevant documents were approved by 
the appropriate independent ethics committee or insti-
tutional review board for each participating site prior to 
initiation.
Patients
Eligible patients were men and women aged ≥18  years 
with a body mass index between 18 and 35  kg/m2 
at screening. HCV RNA levels were required to be 
≥100,000  IU/mL, based on reports of lower SVR rates 
with alfa/RBV therapy in patients with high viral load, 
particularly those with genotype 3 infection, suggesting 
a greater medical need for improved therapies for this 
patient population (Andriulli et al. 2008; Mecenate et al. 
2010). Cirrhosis status was determined by liver biopsy or 
FibroScan. For liver biopsies, absence of cirrhosis (Ishak 
fibrosis score ≤4 or Metavir score ≤3) was documented 
within 3  years prior to study enrollment, while biop-
sies demonstrating cirrhosis (Ishak score ≥5 or Metavir 
score =  4) could be from any time prior to enrollment. 
FibroScan results (cirrhosis defined as ≥14.6  kPa) were 
required within 1  year of enrollment. Women of child-
bearing potential and men with female partners of child-
bearing potential were required to use highly effective 
contraception throughout treatment. Major exclusion 
criteria included coinfection with hepatitis B virus or 
human immunodeficiency virus, or a history of hepato-
cellular carcinoma, decompensated liver disease, or any 
chronic liver disease other than HCV. Laboratory exclu-
sion criteria included hemoglobin ≤12  g/dL for women 
and ≤13  g/dL for men, platelets <90  ×  106/L, absolute 
neutrophil count ≤1.5  ×  109/L, albumin ≤35  g/L, cre-
atinine clearance ≤50 mL/min, total bilirubin ≥2 mg/dL 
or >1.8  ×  the upper limit of normal [ULN for cirrhot-
ics (unless Gilbert’s disease was present)], alanine 
aminotransferase (ALT) ≥5  ×  ULN, and electrocardio-
graphic abnormality (QTcF >500 ms).
Endpoints and assessments
The primary endpoint was sustained virologic response 
at post-treatment Week 12 (SVR12) in the combined 
genotype 2 and 3 patient population, defined as a plasma 
HCV RNA measurement below the assay lower limit of 
quantitation (LLOQ; 25  IU/mL) target detected or not 
detected. Secondary efficacy endpoints included the 
proportion of patients with undetectable HCV RNA at 
Week 4 (rapid virologic response; RVR), Weeks 4 and 12 
(extended rapid virologic response on treatment; eRVR), 
Week 12 (complete early virologic response; cEVR), end-
of-treatment response (EOTR), and the proportion of 
genotype 3-infected patients with SVR12.
Virologic failure was defined as either on-treatment 
virologic breakthrough or post-treatment relapse. Break-
through was defined as a confirmed increase in HCV 
RNA >1 log10  IU/mL above nadir or a confirmed HCV 
RNA level ≥LLOQ after being <LLOQ. Relapse was 
defined as HCV RNA ≥LLOQ post-treatment following 
an EOTR. Virologic futility criteria for early discontinua-
tion of study drug were failure to achieve ≥2 log10 IU/mL 
reduction from baseline at treatment Week 12 with either 
peginterferon without DCV, and virologic breakthrough 
in patients receiving Lambda/RBV with DCV.
Safety endpoints included proportions of patients with 
AEs, serious AEs, dose reductions and discontinuations 
for AEs, proportions of patients with treatment-emergent 
cytopenic abnormalities (hemoglobin <10 g/dL, absolute 
neutrophils <0.75 ×  109/L, platelets <50 ×  109/L), pro-
portions of patients with on-treatment interferon-related 
flu-like symptoms (pyrexia, chills, pain), musculoskeletal 
symptoms (myalgia, arthralgia, back pain), or constitu-
tional symptoms (fatigue, asthenia), and treatment-emer-
gent laboratory abnormalities.
HCV genotype was assessed using the VERSANT HCV 
genotype 2.0 assay (LiPA; Siemens, Washington, DC, 
USA) and HCV RNA using the COBAS® AmpliPrep/
COBAS® TaqMan® HCV Test version 2.0 (Roche, Pleas-
anton, CA, USA). HCV RNA measurements were taken 
at screening, baseline, on-treatment Weeks 1, 2, 4, 8, 
12, 16, 20, and 24 (as applicable), and post-treatment 
Weeks 4, 12, 24, 36, and 48 (as applicable). Population-
based sequencing of the HCV NS5A region derived from 
plasma samples from all patients at baseline, and from 
patients experiencing virologic failure was performed 
when HCV RNA was ≥1000 IU/mL.
Statistical analysis
Efficacy analyses were based on a modified intention-
to-treat approach (mITT) including all patients who 
received at least one dose of study medication. Observed 
values based on all patients with HCV RNA data at the 
relevant time point were also derived. Treatment com-
parisons were conducted for each of the two Lambda-
containing arms versus the alfa/RBV arm, each at a 
significance level of 0.025. For the primary endpoint 
of SVR12 in the combined genotype 2 and genotype 3 
patient population, treatment comparisons of both the 
Lambda arms versus the alfa arm were conducted as 
two-stage evaluations where superiority was tested only 
if non-inferiority was first established. The treatment dif-
ference in SVR12 and the associated two-sided 97.5  % 
confidence interval (CI) were estimated using a Mantel–
Haenszel approach stratified by the randomization strata. 
Non-inferiority was inferred if the lower bound of the 
97.5 % CI for the treatment difference exceeded −10 %. 
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Superiority was inferred subsequently if the comparison 
showed non-inferiority and the lower bound of the 97.5 % 
CI exceeded 0 %. Because superiority was not evaluated 
unless non-inferiority was established, no adjustment to 
the significance level was made.
Target enrollment was 875 patients, randomly assigned 
in a 2:2:1 distribution of 350 in each Lambda arm and 
175 in the alfa/RBV comparator arm. Assuming a −10 % 
non-inferiority margin and response rates of 80  % for 
alfa/RBV and 82 % for both Lambda/RBV and Lambda/
RBV  +  DCV, these sample sizes were predicted to 
give 90  % power to demonstrate the non-inferiority of 
Lambda to alfa for each comparison (SVR12). Assum-
ing an 80 % response on alfa/RBV and a 92 % response 
in each Lambda arm, and also assuming a two-sided 
type I error of 0.025, the above sample sizes were also 
predicted to give 90  % power to demonstrate superior-
ity of Lambda to alfa for each comparison. A multivari-
ate logistic regression analysis was performed to evaluate 
the effects of baseline factors on SVR12 rates in patients 
treated with the DCV-containing regimen. In the logistic 
regression, the dependent variable was SVR12 status (yes 
or no) and the independent variables (covariates) were 
the baseline factors. The probability of achieving SVR12 
based on those covariates was estimated using a logistic 
function, which is the cumulative logistic distribution.
Results
Patient disposition and baseline characteristics
A total of 1243 patients were screened; 880 were rand-
omized and 874 treated (Fig.  1). Most of the patients 
screened but not randomized (324/363; 89  %) did not 
meet study inclusion criteria. Six patients were rand-
omized but not treated; one withdrew consent, one was 
lost to follow-up, one was a screening failure randomized 
in error, and three were found not to meet study crite-
ria for drug/alcohol use or other significant protocol 
deviations.
Cirrhotic patients comprised 7 % (65/874) of the total 
population (Table  1), with 77  % of diagnoses (50/65) 
made using FibroScan. Baseline characteristics were gen-
erally balanced between treatment arms and between 
HCV genotype groups, although there was a slightly 
higher incidence of cirrhosis among patients with geno-
type 3 (9 %) than genotype 2 (6 %), and a smaller propor-
tion of patients with genotype 3 (46 %) than genotype 2 
(60 %) had an IL28B CC genotype (rs12979860).
Efficacy
SVR12 was achieved by 83 % (95 % CI 78.5, 86.5) in the 
Lambda/RBV +  DCV group, 68  % (95  % CI 63.1, 72.9) 
in the Lambda/RBV group, and 73  % (95  % CI 66.6, 
79.9) in the alfa/RBV group. In the primary analysis, 
Lambda/RBV +  DCV demonstrated superiority to alfa/
RBV, with a treatment difference of 9 % and a 97.5 % CI 
(0.3, 17.6). In contrast, SVR12 for Lambda/RBV versus 
alfa/RBV did not meet prespecified non-inferiority cri-
teria, with a treatment difference of −6  % and a 97.5  % 
CI (−14.9, 3.4) whose lower limit was not above −10 % 
(Table 2). SVR12 rates were lower in patients with cirrho-
sis than in those without cirrhosis in all three treatment 
arms. SVR12 rates in patients with cirrhosis versus those 
without cirrhosis were 48  % versus 69  % for Lambda/
RBV, 65  % versus 84  % for Lambda/RBV  +  DCV, and 
57 % versus 74 % for alfa/RBV.
In subgroup analyses, there were no notable effects on 
Lambda/RBV versus alfa/RBV treatment differences with 
respect to gender, race (white or Asian), Hispanic/Latino 
ethnicity, HCV genotype, IL28B genotype, geographic 
region, or cirrhosis status (Fig. 2a). The treatment differ-
ence slightly favored alfa/RBV for patients with a body 
mass index ≥30  kg/m2 (97.5  % CI did not cross zero), 
although patient numbers were relatively small (Lambda/
RBV, n  =  54; alfa/RBV, n  =  21). Treatment differences 
favored Lambda/RBV + DCV over alfa/RBV (97.5 % CI 
did not cross zero) in patients >65 years old and in His-
panic patients, although patient numbers were low for 
both comparisons (Fig.  2b). Lambda/RBV  +  DCV was 
also favored in patients with HCV genotype 2, patients 
with IL28B non-CC genotypes, non-cirrhotic patients, 
and patients in Asia (Fig. 2).
Genotype 2
Both Lambda arms tended to have higher SVR12 rates 
among patients infected with genotype 2 compared 
with genotype 3 (Table 2). Among genotype 2-infected 
patients, SVR12 was achieved by 90 % in the Lambda/
RBV  +  DCV group, 72  % in the Lambda/RBV group, 
and 74 % in the alfa/RBV group. One additional patient 
receiving Lambda/RBV + DCV had HCV RNA <LLOQ 
TD at week 12 and was therefore defined as a treatment 
failure per the study protocol; however, HCV RNA was 
<LLOQ TND at all post-treatment visits. The 12-week 
regimen of Lambda/RBV +  DCV achieved non-inferi-
ority to the 24-week regimen of alfa/RBV for SVR12 in 
patients infected with genotype 2, with a treatment dif-
ference of 16 % and 97.5 % CI (4.2, 27.2), whose lower 
limit was above −10  %. In patients with genotype 2 
infection, SVR12 rates were similar in patients with or 
without cirrhosis: 73  % versus 71  % (Lambda/RBV), 
92  % versus 89  % (Lambda/RBV  +  DCV), and 67  % 
versus 74 % (alfa/RBV). Further assessment of patients 
treated with Lambda/RBV  +  DCV, based on multi-
variate logistic regression analysis, found no signifi-
cant effect of patient baseline factors on SVR12 rates in 
patients with HCV genotype 2.
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Genotype 3
Among genotype 3-infected patients, SVR12 was 
achieved by 75  % in the Lambda/RBV  +  DCV group, 
64 % in the Lambda/RBV group, and 73 % in the alfa/RBV 
group. The 12-week regimen of Lambda/RBV + DCV did 
not achieve non-inferiority to the 24-week regimen of 
alfa/RBV for SVR12 in patients infected with genotype 
3. The failure of Lambda/RBV +  DCV to achieve non-
inferiority for SVR12 in genotype 3 infection was driven 
by a higher rate of post-treatment relapse in genotype 
3 (19 %) than genotype 2 (6 %). As noted earlier, SVR12 
rates were higher among patients without cirrhosis in 
all treatment arms; this difference was driven primar-
ily by SVR12 rates in patients with genotype 3 infection, 
among whom SVR12 rates for those with or without cir-
rhosis were 29 % versus 67 % (Lambda/RBV), 43 % versus 
78 % (Lambda/RBV + DCV), and 50 % versus 75 % (alfa/
RBV). In addition, there were more patients with cir-
rhosis among the genotype 3-infected group. Multivari-
ate logistic regression analysis found both cirrhosis and 
the baseline NS5A-Y93H polymorphism to be negative 
predictors of SVR12 among genotype 3-infected patients 
when treated for 12 weeks with Lambda/RBV + DCV.
Resistance
Genotype 2
Baseline NS5A sequences were available for 173/184 
genotype 2-infected patients who were treated with 
Fig. 1 Patient disposition. Alfa peginterferon alfa‑2a, DCV daclatasvir, Lambda peginterferon Lambda‑1a, mITT modified intention‑to‑treat, RBV 
ribavirin
Page 6 of 12Foster et al. SpringerPlus  (2016) 5:1365 
Table 1 Baseline demographics and disease characteristics
alfa peginterferon alfa-2a, BL baseline, DCV daclatasvir, HCV hepatitis C virus, Lambda peginterferon Lambda-1a, RBV ribavirin, SD standard deviation
Parameter 24 weeks lambda/RBV
N = 353
12 weeks lambda/RBV + DCV
N = 349
24 weeks alfa/RBV
N = 172
Age, mean (range), years 48 (20, 72) 47 (18, 74) 46 (21, 73)
Male, n (%) 210 (59) 195 (56) 93 (54)
Race/ethnicity, n (%)
 White 232 (66) 226 (65) 111 (64)
 Black/African American 4 (1) 5 (1) 3 (2)
 Asian 113 (32) 118 (34) 55 (32)
 Other 4 (1) 0 3 (2)
 Hispanic/Latino ethnicity 45 (13) 48 (14) 17 (10)
BL HCV RNA, mean (SD) (log10 IU/mL) 6 (1) 6 (1) 6 (1)
HCV RNA distribution (IU/mL)
 ≥800,000 269 (76) 276 (79) 132 (77)
HCV genotype, n (%)
 Genotype 2 183 (52) 184 (53) 91 (53)
 Genotype 3 170 (48) 165 (47) 81 (47)
Cirrhosis, n (%) 25 (7) 26 (7) 14 (8)
 By biopsy 9 (3) 4 (1) 2 (1)
 By FibroScan 16 (5) 22 (6) 12 (7)
IL28B genotype (RS12979860), n (%)
 CC 180 (51) 192 (55) 94 (55)
 CT 145 (42) 126 (36) 68 (40)
 TT 27 (8) 28 (8) 10 (6)
Body mass index >30 kg/m2, n (%) 54 (15) 62 (18) 21 (12)
Table 2 Primary and secondary efficacy endpoints
alfa peginterferon alfa-2a, cEVR complete early virologic response, CI confidence interval, DCV daclatasvir, diff. difference, EOTR end-of-treatment response, eRVR 
extended rapid virologic response, Lambda peginterferon Lambda-1a, N/A not available, RBV ribavirin, RVR rapid virologic response, SVR12 sustained virologic 
response at post-treatment Week 12, SVR24 sustained virologic response at post-treatment Week 24
a Lambda-alfa difference adjusted for randomization strata. Non-inferior if lower CI bound is >−10 %; superior if both non-inferior and lower CI bound is >0 %
b The study was terminated before the 24 week follow-up visit of 14 patients with SVR12, hence SVR24 data for these 14 patients are unavailable
Parameter,  % (n/N), except where indicated 24 weeks lambda/RBV
N = 353
12 weeks lambda/RBV + DCV
N = 349
24 weeks alfa/RBV
N = 172
SVR12a 68 (240/353) 83 (288/349) 73 (126/172)
Treatment diff. (97.5 % CI)a −6 (−14.9, 3.4) 9 (0.3, 17.6) N/A
SVR12 genotype 3 64 (109/170) 75 (123/165) 73 (59/81)
Treatment diff. (97.5 % CI)a −9 (−22.3, 4.2) 1 (−11.5, 14.3) N/A
  SVR12 genotype 3 with cirrhosis 29 (4/14) 43 (6/14) 50 (4/8)
SVR12 genotype 2 72 (131/183) 90 (165/184) 74 (67/91)
Treatment diff. (97.5 % CI) −3 (−15.5, 9.9) 16 (4.2, 27.2) N/A
  SVR12 genotype 2 with cirrhosis 73 (8/11) 92 (11/12) 67 (4/6)
SVR24b 66 (232/353) 82 (285/349) 72 (123/172)
Treatment diff. (97.5 % CI)a −6 (−15.5, 2.9) 10 (1.1, 18.4) N/A
RVR 64 (227/353) 86 (299/349) 58 (99/172)
eRVR 59 (210/353) 83 (288/349) 56 (97/172)
cEVR 86 (302/353) 93 (324/349) 87 (150/172)
EOTR 86 (303/353) 95 (332/349) 92 (158/172)
Virologic breakthrough 5 (16/353) 1 (2/349) 2 (3/172)
Relapse 14 (51/353) 12 (43/349) 13 (23/172)
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Lambda/RBV  +  DCV (Additional file  1: Table S1a). 
Among these 173 patients, 17 were reported as not 
achieving SVR12. Three of these 17 non-SVR12 patients 
received ≤4  weeks of treatment due to death, with-
drawn consent, or loss to follow-up while one patient 
actually achieved SVR (described above). All 17 non-
SVR12 patients had baseline NS5A polymorphisms at 
positions F28 and/or L31. However, most patients with 
these common polymorphisms achieved SVR12. SVR12 
was achieved by 89  % (57/64) and 91  % (99/109) of 
patients with or without baseline F28 polymorphisms, 
respectively, and by 88 % (103/117) and 95 % (53/56) of 
patients with or without baseline L31 polymorphisms, 
respectively. Thirteen genotype 2-infected patients with 
virologic failure had NS5A sequence data at both base-
line and failure (Additional file  1: Table S2a). At fail-
ure, NS5A resistance-associated variants (RAVs) were 
detected in these 13 patients at positions F28 (1/13), 
L31 (5/13), or F28 and L31 (7/13). Treatment-emergent 
NS5A RAVs were present in 46  % (6/13) of patients at 
F28 (n = 4) or L31 (n = 2).
Genotype 3
Baseline NS5A sequences were available for all 
165 patients with genotype 3 infection who were 
treated with Lambda/RBV + DCV (Additional file 1: 
Table S1b). SVR12 was achieved by 63  % (24/38) of 
patients with NS5A polymorphisms at M28, A30, 
L31, and/or Y93, and by 78  % (99/127) of patients 
without polymorphisms at any of these positions. 
SVR12 rates in patients with or without baseline 
NS5A polymorphisms at M28 or A30 were compa-
rable. SVR12 was achieved by 50  % (2/4) and 75  % 
(121/161) of patients with or without M28 polymor-
phisms, respectively, and by 72  % (18/25) or 75  % 
(105/140) of patients with or without A30 poly-
morphisms, respectively. SVR12 rates in patients 
without baseline NS5A-Y93H (77  %, 119/154) were 
higher than in patients with this polymorphism 
(36  %, 4/11). Two patients had L31 polymorphisms 
at baseline; both achieved SVR12. NS5A sequencing 
data were available at both baseline and failure for 
38/42 genotype 3-infected patients with virologic 
failure (Additional file  1: Table S2b). NS5A-Y93H 
was the most frequent RAV detected in this group, 
including 26/38 patients (68  %) with treatment-
emergent Y93H and 7/38 (18  %) with Y93H at both 
baseline and failure. Emergent M28A, A30K, and 
L31F were present in 1/38, 1/38, and 1/38 patients, 
respectively.
Fig. 2 Treatment differences and 97.5 % confidence intervals by subgroup. a Subgroup analysis of the Lambda/RBV versus alfa/RBV treatment 
difference and 97.5 % confidence intervals. b Subgroup analysis of the Lambda/RBV + DCV versus alfa/RBV treatment difference and 97.5 % confi‑
dence intervals. alfa peginterferon alfa‑2a, BMI body mass index, DCV daclatasvir, GT genotype, Lambda peginterferon Lambda‑1a, RBV ribavirin
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Safety
There were no unexpected AE signals; observed events 
were consistent with known alfa/RBV toxicities and with 
previous clinical study data for Lambda/RBV (Table  3). 
The incidence of all-grade AEs ranged from 86  % to 
97  % in the three treatment arms. Dose reductions of 
both interferon and RBV were less common in the two 
Lambda arms than in the alfa/RBV arm. Almost all 
dose reductions in alfa/RBV recipients were due to AEs, 
whereas the majority of reductions in Lambda recipients 
were due to elevated liver function tests.
Grade 3–4 laboratory abnormalities were more com-
mon in the alfa/RBV arm, due primarily to cytopenias. 
Patients receiving Lambda/RBV had numerically fewer 
cytopenic abnormalities, flu-like and musculoskeletal 
events than those receiving alfa/RBV. Patients receiv-
ing Lambda/RBV  +  DCV had significantly fewer cyto-
penic abnormalities than patients receiving alfa/RBV 
(3 % vs 36 %; p < 0.0001), and numerically fewer flu-like 
and musculoskeletal events. RBV dose reduction was 
most common in the alfa/RBV arm (19  %) whereas the 
Lambda/RBV  +  DCV arm had the lowest rate of RBV 
dose reduction (3 %). Grade 3–4 anemia was observed in 
5  % of the alfa/RBV group versus <1  % in the Lambda/
RBV + DCV group. Grade 3–4 bilirubin elevations were 
observed in 8 % of the Lambda/RBV group and in 3 % of 
the Lambda/RBV + DCV group with no grade 3–4 eleva-
tions in the alfa/RBV group. Grade 3–4 ALT elevations 
were observed in 6 % of the Lambda/RBV group, 4 % of 
the Lambda/RBV/DCV group, and 3  % of the alfa/RBV 
group. Overall, the 12-week Lambda/RBV + DCV regi-
men appeared better tolerated than either of the 24-week 
arms (Table 3) with the lowest proportion of grade 3–4 
AEs, discontinuations for AEs, and RBV dose reductions.
Three hepatic decompensation events were reported. 
A 63-year-old female with cirrhosis and a history of 
esophageal varices experienced hepatic decompensa-
tion during treatment with Lambda/RBV  +  DCV, and 
was discontinued from study drug on study Day 35. This 
patient later died of renal failure and septic shock at post-
treatment Week 4. A 58-year-old male with cirrhosis 
experienced hepatic failure leading to discontinuation 
of Lambda/RBV on Day 91; the event was considered 
resolved on Day 115. A 56-year-old male experienced 
decompensated cirrhosis with elevated total bilirubin, 
encephalopathy, and ascites leading to discontinuation 
of Lambda/RBV + DCV therapy on Day 64. The biliru-
bin elevation improved progressively post-treatment and 
was considered resolved on day 162. In addition to these 
patients, a 40-year-old male with a history of fatty liver 
and Gilbert’s syndrome experienced ALT and aspartate 
aminotransferase (AST) increases leading to interrup-
tion of Lambda/RBV treatment on Day 56; treatment at 
a reduced dose resumed on Day 78. The patient com-
pleted blinded therapy but subsequent extended therapy 
with Lambda/RBV was discontinued on Day 146 after the 
events worsened to grade 4. ALT and AST levels were 
normal on Day 189.
Discussion
This phase 3, randomized, double-blind study compared 
the efficacy and safety of Lambda/RBV, with and without 
DCV, with that of alfa/RBV in treatment-naive patients 
with genotype 2 or 3 infection. In a direct comparison of 
interferon/RBV treatment over 24  weeks, the endpoint 
of non-inferiority of Lambda/RBV versus alfa/RBV was 
not met for the primary endpoint of SVR12. This finding 
was unexpected, since phase 2 clinical data for genotypes 
2 and 3 from the dose-ranging EMERGE study (Muir 
et  al. 2014) showed a numerically higher SVR12 rate 
with Lambda (180 μg) plus RBV than with alfa/RBV after 
24 weeks of treatment (76 vs 57 %). However, whereas the 
proportions of genotype 3 to genotype 2 in the Lambda 
and alfa arms of the EMERGE study (41–50 %) were simi-
lar to this study, patient numbers (29–30 patients per 
arm) were much lower.
In contrast, 12  weeks of triple therapy with Lambda/
RBV and DCV was superior to 24  weeks of alfa/RBV 
for the primary endpoint, and also superior for early 
on-treatment (RVR) response. High SVR12 rates were 
achieved in patients with genotype 2 infection, with no 
significant impact of baseline demographic or disease 
characteristics, including cirrhosis status. However, the 
12-week regimen was found to be less efficacious among 
patients with genotype 3, primarily due to a higher rate 
of relapse. This finding is similar to that noted with 
12 weeks of sofosbuvir with RBV; extension of that regi-
men to 24  weeks resulted in a significantly higher SVR 
rate (Zeuzem et  al. 2014). Genotype 3-infected patients 
with cirrhosis had substantially lower responses than 
those without cirrhosis; this difference was significant 
in multivariate analysis. The difference was larger in the 
Lambda arms than in the alfa/RBV arm. Treatment dif-
ferences related to cirrhosis status in genotype 3 infec-
tion, together with the shorter duration of treatment 
with Lambda/RBV + DCV, may have contributed to the 
higher relapse rate for Lambda/RBV  +  DCV in geno-
type 3. Prolonging therapy for 24 weeks may potentially 
increase SVR12 rates in genotype 3-infected patients and 
reduce the impact of baseline factors; however, this has 
not been studied.
Baseline NS5A polymorphisms associated with DCV 
resistance in patients treated with Lambda/RBV + DCV 
had a greater impact in genotype 3 infection than in 
genotype 2. Most patients with genotype 2 infection had 
baseline polymorphisms at F28 and/or L31; however, 
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Table 3 On-treatment safety
AE adverse event, alfa peginterferon alfa-2a, ALT alanine aminotransferase, AST aspartate aminotransferase, Lambda peginterferon Lambda-1a, RBV ribavirin, SAE 
serious adverse event, ULN upper limit of normal
a Flu-like symptoms defined as pyrexia, chills, or pain
b Musculoskeletal events defined as myalgia, arthralgia, or back pain
c Cytopenic abnormalities defined as hemoglobin <10 g/dL, absolute neutrophils <750 cells/mm3, or platelets <50,000 cells/mm3
Parameter, n (%) 24 weeks lambda/RBV
N = 353
12 weeks lambda/RBV + DCV
N = 349
24 weeks alfa/RBV
N = 172
Total with AEs (all grades) 316 (90) 299 (86) 166 (97)
Death 0 1 (<1) 0
Grade 3–4 AEs 48 (14) 24 (7) 60 (35)
SAEs 22 (6) 10 (3) 4 (2)
AEs leading to discontinuation 26 (7) 10 (3) 15 (9)
Interferon dose reductions 25 (7) 10 (3) 50 (29)
  For adverse events 8 (2) 6 (2) 47 (27)
  For elevated liver function tests 18 (5) 5 (1) 3 (2)
Ribavirin dose reductions 21 (6) 12 (3) 33 (19)
  For adverse events 16 (5) 11 (3) 33 (19)
  For elevated liver function tests 5 (1) 1 (<1) 0
Notable AEs
 Fatigue 110 (31) 87 (25) 74 (43)
 Influenza‑like illness 26 (7) 18 (5) 36 (21)
 Asthenia 43 (12) 35 (10) 23 (13)
 Pyrexia 20 (6) 23 (7) 41 (24)
 Pruritus 109 (31) 82 (23) 50 (29)
 Nausea 88 (25) 71 (20) 51 (30)
 Insomnia 110 (31) 74 (21) 50 (29)
 Headache 64 (18) 47 (13) 44 (26)
 Dizziness 34 (10) 46 (13) 38 (22)
 Myalgia 49 (14) 45 (13) 60 (35)
 Arthralgia 48 (14) 44 (13) 49 (28)
 Decreased appetite 68 (19) 51 (15) 55 (32)
 Anemia 14 (4) 14 (4) 35 (20)
 Neutropenia 1 (<1) 1 (<1) 53 (31)
 Depression 29 (8) 16 (5) 14 (8)
Composite AEs
 Interferon‑associated flu‑like symptomsa 41 (12) 32 (9) 63 (36)
 Musculoskeletal eventsb 90 (26) 72 (21) 85 (49)
Treatment‑emergent grade 3–4 laboratory abnormalities
 Hemoglobin <9.0 g/L 2 (<1) 1 (<1) 8 (5)
 Platelet count <5 × 104/mm3 0 0 7 (4)
 Leukocytes <1.5 × 103/mm3 0 0 23 (13)
 Lymphocytes <5 × 102/mm3 1 (<1) 5 (1) 29 (17)
 Neutrophils <7.5 × 102/mm3 0 0 47 (27)
 ALT >5.0 × ULN 22 (6) 13 (4) 5 (3)
 AST >5.0 × ULN 33 (9) 12 (3) 5 (3)
 Gamma‑glutamyl transferase >5.0 × ULN 16 (5) 6 (2) 2 (1)
 Total bilirubin >2.5 × ULN 27 (8) 9 (3) 0
 Direct bilirubin >1.2 mg/dL 20 (6) 10 (3) 0
Composite treatment‑emergent grade 3–4 laboratory abnormalities
 Cytopenic abnormalitiesc 10 (3) 7 (2) 63 (36)
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differences in SVR12 rates in patients with or without 
these polymorphisms at baseline were modest. Baseline 
NS5A polymorphisms associated with DCV resistance 
were less common in patients with genotype 3 infection. 
However, 36 % of patients with Y93H at baseline achieved 
SVR12, compared with 77  % of patients without this 
baseline polymorphism. Moreover, Y93H was present 
post-failure in 86 % of genotype 3-infected patients who 
experienced virologic failure. Multivariate logistic regres-
sion analysis identified the presence of Y93H as having 
a significant adverse impact on SVR12 among genotype 
3-infected patients. In follow-up studies, persistence of 
NS5A resistance variants was variable in patients who 
failed therapy with DCV-based regimens (Reddy et  al. 
2014). Partial or complete replacement of NS5A variants 
was observed in some patients after 1–2  years of post-
treatment follow-up; however, the potential relevance of 
these findings to retreatment strategies has not yet been 
established.
The safety profiles of Lambda/RBV and Lambda/
RBV  +  DCV in this study were consistent with previ-
ous studies of Lambda/RBV (Muir et  al. 2014; Vierling 
et  al. 2013). The lower incidences of hematologic, mus-
culoskeletal, and flu-like symptoms and lower rates of 
dose adjustment for Lambda-based regimens versus 
alfa-2a that were observed are consistent with the more 
restricted extrahepatic distribution of the Type III recep-
tor and its virtual absence from bone marrow progenitors 
and peripheral blood cells (Andersen et al. 2013). There 
were no unexpected safety findings. The proportions of 
grade 3–4 aminotransferase and bilirubin elevations over 
24  weeks on Lambda/RBV in this study were similar to 
those seen over 24 weeks in the EMERGE genotype 2 and 
3 population among patients receiving 120 or 180 μg of 
Lambda. Similarly, the proportions of grade 3–4 ami-
notransferase and bilirubin elevations over 12  weeks 
of Lambda/RBV +  DCV (≈3.5 and ≈3  %, respectively) 
were comparable to those observed with the same regi-
men over 24 weeks in the phase 2 D-LITE study (5 and 
3  %, respectively; Muir et  al. 2014; Vierling et  al. 2013). 
Hepatic decompensation occurred in 3 patients, all with 
prior evidence of portal hypertension. Similar events 
have been reported in previous studies using alfa inter-
ferons (Hezode et al. 2013).
In conclusion, the results of this large multinational 
phase 3 study in treatment-naive HCV genotype 2 and 3 
infection demonstrated that 12 weeks of treatment with 
Lambda/RBV and DCV gave a superior SVR12 rate com-
pared with 24 weeks of alfa/RBV in the combined popula-
tion of patients with genotype 2 or 3 infection. However, 
the regimen was less effective among genotype 3-infected 
patients with cirrhosis. The shorter, Lambda-containing 
regimen also demonstrated better tolerability than alfa/
RBV and a lower incidence of interferon and/or RBV 
dose adjustments, consistent with phase 2 clinical data 
for Lambda/RBV with and without DCV. Despite the 
encouraging efficacy and safety outcomes of the Lambda/
RBV + DCV regimen in this study, further development 
of this regimen was discontinued due to the emergence 
of highly efficacious and well-tolerated all-oral DAA 
combination regimens. However, data from the current 
study remain relevant in the context of understanding the 
clinical profile of DCV, which has been widely approved 
as a component of all-oral HCV regimens.
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